Belite Bio (BLTE) Earnings Date & Reports

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

BLTE is expected to report earnings to rise 125.79% to -76 cents per share on August 12

Q2'26

Est.

$-0.77

Q1'26

Beat

by $0.30

Q4'25

Beat

by $0.15

Q3'25

Beat

by $0.22

Q2'25

Beat

by $0.08

The last earnings report on May 20 showed earnings per share of -34 cents, beating the estimate of -63 cents. With 106.21K shares outstanding, the current market capitalization sits at 5.81B.

View a ticker or compare two or three

Compare

BLTE

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for BLTE